Skip to main content

Phase II trial of isotretinoin and recombinant interferon alfa-2a in metastatic colorectal carcinoma.

Publication ,  Journal Article
Pazdur, R; Bready, B; Ajani, JA; Abbruzzese, JL; Markowitz, A; Sugarman, S; Jones, D; Levin, B
Published in: Am J Clin Oncol
October 1995

Phase II trials of the novel biologic combination isotretinoin (13-cis-retinoic aid) plus recombinant interferon alfa-2a have demonstrated this combination's major activity against advanced squamous cell carcinoma of the skin and cervix. Because this combination has had limited study in other tumors, we initiated a phase II trial of this regimen in patients with metastatic colorectal adenocarcinoma. Sixteen patients with measurable metastatic colon carcinoma who had received no previous chemotherapy were entered on the trial. Patients received recombinant interferon alfa-2a, 6 million units a day subcutaneously, and isotretinoin, 1 mg/kg per day orally in two divided doses. Patients were evaluated for response after 8 weeks of treatment and then continued on therapy until progressive disease was documented. We did not observe complete or partial responses. Two patients experienced minor responses in measurable pulmonary metastases lasting 12 and 8 weeks. Grade 3-4 toxic reactions included fatigue (5 patients), granulocytopenia (6 patients), neurotoxicity (2 patients), and elevated serum triglyceride levels (2 patients). Although this combination has demonstrated significant activity in squamous cell carcinomas of the skin and cervix, our results suggest that it has little therapeutic activity against advanced colorectal adenocarcinomas.

Duke Scholars

Published In

Am J Clin Oncol

DOI

ISSN

0277-3732

Publication Date

October 1995

Volume

18

Issue

5

Start / End Page

436 / 438

Location

United States

Related Subject Headings

  • Recombinant Proteins
  • Oncology & Carcinogenesis
  • Male
  • Isotretinoin
  • Interferon-alpha
  • Interferon alpha-2
  • Humans
  • Female
  • Colorectal Neoplasms
  • Antineoplastic Combined Chemotherapy Protocols
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Pazdur, R., Bready, B., Ajani, J. A., Abbruzzese, J. L., Markowitz, A., Sugarman, S., … Levin, B. (1995). Phase II trial of isotretinoin and recombinant interferon alfa-2a in metastatic colorectal carcinoma. Am J Clin Oncol, 18(5), 436–438. https://doi.org/10.1097/00000421-199510000-00015
Pazdur, R., B. Bready, J. A. Ajani, J. L. Abbruzzese, A. Markowitz, S. Sugarman, D. Jones, and B. Levin. “Phase II trial of isotretinoin and recombinant interferon alfa-2a in metastatic colorectal carcinoma.Am J Clin Oncol 18, no. 5 (October 1995): 436–38. https://doi.org/10.1097/00000421-199510000-00015.
Pazdur R, Bready B, Ajani JA, Abbruzzese JL, Markowitz A, Sugarman S, et al. Phase II trial of isotretinoin and recombinant interferon alfa-2a in metastatic colorectal carcinoma. Am J Clin Oncol. 1995 Oct;18(5):436–8.
Pazdur, R., et al. “Phase II trial of isotretinoin and recombinant interferon alfa-2a in metastatic colorectal carcinoma.Am J Clin Oncol, vol. 18, no. 5, Oct. 1995, pp. 436–38. Pubmed, doi:10.1097/00000421-199510000-00015.
Pazdur R, Bready B, Ajani JA, Abbruzzese JL, Markowitz A, Sugarman S, Jones D, Levin B. Phase II trial of isotretinoin and recombinant interferon alfa-2a in metastatic colorectal carcinoma. Am J Clin Oncol. 1995 Oct;18(5):436–438.

Published In

Am J Clin Oncol

DOI

ISSN

0277-3732

Publication Date

October 1995

Volume

18

Issue

5

Start / End Page

436 / 438

Location

United States

Related Subject Headings

  • Recombinant Proteins
  • Oncology & Carcinogenesis
  • Male
  • Isotretinoin
  • Interferon-alpha
  • Interferon alpha-2
  • Humans
  • Female
  • Colorectal Neoplasms
  • Antineoplastic Combined Chemotherapy Protocols